Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Poor neutrophil recovery following CD19-targeted CAR-T cell therapy predicts inferior outcomes in adult patients with B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSatoshi KoiYYYu YagiFOFumihiko Ouchi

Discussion

Loading...

Member takes

Overview

Findings reveal that poor neutrophil recovery predicts reduced progression-free survival in adults with B-cell lymphoma, suggesting CAR-T efficacy is impaired.

Key Points

  • Poor neutrophil recovery resulted in significantly lower progression-free survival, with rates at 49% compared to 78%.
  • Among the 74 adult B-cell lymphoma patients analyzed, 24 had neutrophil counts below 500/μL 28 days post-infusion.
  • Observational analysis assessed neutrophil recovery and its impact on CAR-T cell therapeutic outcomes using multivariate analysis.
  • Research indicates the need for further studies to understand the mechanisms connecting hematologic recovery with CAR-T cell efficacy.

Cite This Study

Koi et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e25ahttps://doi.org/10.1182/blood-2025-5496
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival2025
  2. 2Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy2025
  3. 3Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy2025
  4. 4Modified beac as bridging/lymphodepletion therapy followed by CAR-T and autologous stem cell support in relapsed or refractory DLBCL patients: Insights from safety and efficacy outcomes in 12 patients2025
  5. 5Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis2025